Bracing for Volume-Based Procurement in China

Published on January 19, 2023

China’s volume-based procurement (VoBP) for pharmaceuticals has been broadening its reach and accelerating pace, with mounting pressure for pharma and medtech majors. Our experts outline actionable approaches to cope with the challenges.

When the going gets tough, the tough get going. The scope of China’s drug procurement policies is broadening. Called volume-based procurement (VoBP) these policies are unfolding at a faster pace and with greater price pressure. As such, pharma companies may need to consider a systematic approach, that would help them plan ahead and brace for imminent impacts.

VoBP policies have shaken up China’s pharma and medtech industries. Since 2018, there have been six rounds of national VoBP for 234 drugs with 53 percent price cuts on average, and…

Continue reading on website
Other news

Introduction to B2B Dynamic Pricing

January 19, 2023
*//*-->*//*-->*//*-->*//*-->*//*-->*/Having helped multiple B2B clients implement dynamic and digital pricing to achieve 4-6 percent margin improvement, we have launched a new series discussing the growth potential, challenges, and pitfalls of B2B dynamic pricing. In our first article, expert Kiran Pudi outlines why, how, and when B2B dynamic pricing should be developed and employed for commercial

Evolving Distribution Channels: How CHCs Can Continue Using the Brick-and-mortar Pharmacy Channel Effectively and Efficiently

January 19, 2023
The way consumers buy medicines has changed significantly in recent years. While brick-and-mortar pharmacies are still by far the most important sales channel, more and more consumers in most countries worldwide seek information online and also buy OTC products in the digital sphere. As a result, the relevance of brick-and-mortar pharmacies is declining, and consumer healthcare providers must ask